Trade Assembly Biosciences, Inc. - ASMB CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.6952 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 0.001 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Assembly Biosciences Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 13.2174 |
Open* | 13.1974 |
1-Year Change* | 1281.78% |
Day's Range* | 12.8974 - 13.1974 |
52 wk Range | 0.64-1.78 |
Average Volume (10 days) | 251.38K |
Average Volume (3 months) | 12.71M |
Market Cap | 52.63M |
P/E Ratio | -100.00K |
Shares Outstanding | 65.79M |
Revenue | N/A |
EPS | -1.43 |
Dividend (Yield %) | N/A |
Beta | 0.52 |
Next Earnings Date | Mar 20, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 22, 2024 | 13.2174 | -0.0200 | -0.15% | 13.2374 | 13.5474 | 13.0874 |
Apr 19, 2024 | 13.3974 | 0.0900 | 0.68% | 13.3074 | 13.6974 | 13.2374 |
Apr 18, 2024 | 13.1374 | 0.6600 | 5.29% | 12.4774 | 13.3274 | 12.1074 |
Apr 17, 2024 | 12.8074 | -1.5900 | -11.04% | 14.3974 | 14.4274 | 12.5074 |
Apr 16, 2024 | 14.5074 | 0.0100 | 0.07% | 14.4974 | 14.7474 | 14.3474 |
Apr 15, 2024 | 14.6474 | -0.0100 | -0.07% | 14.6574 | 15.0974 | 14.3474 |
Apr 12, 2024 | 14.6474 | -0.1000 | -0.68% | 14.7474 | 14.9974 | 14.3474 |
Apr 11, 2024 | 14.9974 | 0.7100 | 4.97% | 14.2874 | 14.9974 | 14.2874 |
Apr 10, 2024 | 14.6674 | 0.4700 | 3.31% | 14.1974 | 14.6674 | 13.8974 |
Apr 9, 2024 | 14.7474 | 0.3400 | 2.36% | 14.4074 | 14.9474 | 13.9974 |
Apr 8, 2024 | 14.1474 | 0.3700 | 2.69% | 13.7774 | 14.4974 | 13.7774 |
Apr 5, 2024 | 13.8674 | 0.6700 | 5.08% | 13.1974 | 14.2074 | 13.0274 |
Apr 4, 2024 | 13.3574 | -0.1500 | -1.11% | 13.5074 | 14.1074 | 13.2974 |
Apr 3, 2024 | 13.4074 | 0.4300 | 3.31% | 12.9774 | 14.3474 | 12.9774 |
Apr 2, 2024 | 13.3474 | 0.3500 | 2.69% | 12.9974 | 13.4874 | 12.7974 |
Apr 1, 2024 | 12.8974 | -0.4000 | -3.01% | 13.2974 | 13.2974 | 12.8974 |
Mar 28, 2024 | 13.2474 | 0.2400 | 1.85% | 13.0074 | 13.4474 | 12.9974 |
Mar 27, 2024 | 13.3074 | 0.5800 | 4.56% | 12.7274 | 13.3674 | 12.7174 |
Mar 26, 2024 | 12.8474 | -0.4500 | -3.38% | 13.2974 | 13.3974 | 12.7374 |
Mar 25, 2024 | 12.9974 | 0.4900 | 3.92% | 12.5074 | 13.3674 | 12.5074 |
Assembly Biosciences, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, May 2, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q1 2024 Assembly Biosciences Inc Earnings Release Q1 2024 Assembly Biosciences Inc Earnings ReleaseForecast -Previous - |
Friday, May 24, 2024 | ||
Time (UTC) 15:00 | Country US
| Event Assembly Biosciences Inc Annual Shareholders Meeting Assembly Biosciences Inc Annual Shareholders MeetingForecast -Previous - |
Wednesday, August 7, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q2 2024 Assembly Biosciences Inc Earnings Release Q2 2024 Assembly Biosciences Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 6.254 | 79.105 | 15.963 | 14.804 |
Total Operating Expense | 94.114 | 138.942 | 143.881 | 118.676 | 107.539 |
Selling/General/Admin. Expenses, Total | 23.906 | 28.503 | 36.86 | 32.919 | 34.798 |
Research & Development | 69.111 | 70.149 | 101.337 | 85.757 | 72.741 |
Operating Income | -94.114 | -132.688 | -64.776 | -102.713 | -92.735 |
Interest Income (Expense), Net Non-Operating | 1.022 | 0.302 | 2.624 | 4.3 | 3.083 |
Net Income Before Taxes | -93.092 | -132.386 | -62.152 | -98.408 | -89.652 |
Net Income After Taxes | -93.092 | -129.855 | -62.152 | -97.634 | -90.751 |
Net Income Before Extra. Items | -93.092 | -129.855 | -62.152 | -97.634 | -90.751 |
Net Income | -93.092 | -129.855 | -62.152 | -97.634 | -90.751 |
Income Available to Common Excl. Extra. Items | -93.092 | -129.855 | -62.152 | -97.634 | -90.751 |
Income Available to Common Incl. Extra. Items | -93.092 | -129.855 | -62.152 | -97.634 | -90.751 |
Diluted Net Income | -93.092 | -129.855 | -62.152 | -97.634 | -90.751 |
Diluted Weighted Average Shares | 48.4093 | 43.2804 | 35.4271 | 26.2588 | 22.8016 |
Diluted EPS Excluding Extraordinary Items | -1.92302 | -3.00032 | -1.75436 | -3.71815 | -3.98002 |
Diluted Normalized EPS | -1.90036 | -2.39523 | -1.59392 | -3.71815 | -3.98002 |
Revenue | 0 | 6.254 | 79.105 | 15.963 | 14.804 |
Total Extraordinary Items | |||||
Other, Net | 0.005 | ||||
Unusual Expense (Income) | 1.097 | 40.29 | 5.684 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Revenue | 0 | 0 | |||
Total Operating Expense | 17.488 | 19.559 | 22.978 | 23.401 | 24.573 |
Selling/General/Admin. Expenses, Total | 4.965 | 5.012 | 5.897 | 5.271 | 6.781 |
Research & Development | 12.523 | 14.547 | 15.984 | 18.13 | 17.792 |
Unusual Expense (Income) | 1.097 | ||||
Operating Income | -17.488 | -19.559 | -22.978 | -23.401 | -24.573 |
Interest Income (Expense), Net Non-Operating | 0.592 | 0.609 | 0.583 | 0.256 | 0.112 |
Net Income Before Taxes | -16.896 | -18.95 | -22.395 | -23.145 | -24.461 |
Net Income After Taxes | -16.896 | -18.95 | -22.395 | -23.145 | -24.461 |
Net Income Before Extra. Items | -16.896 | -18.95 | -22.395 | -23.145 | -24.461 |
Net Income | -16.896 | -18.95 | -22.395 | -23.145 | -24.461 |
Income Available to Common Excl. Extra. Items | -16.896 | -18.95 | -22.395 | -23.145 | -24.461 |
Income Available to Common Incl. Extra. Items | -16.896 | -18.95 | -22.395 | -23.145 | -24.461 |
Diluted Net Income | -16.896 | -18.95 | -22.395 | -23.145 | -24.461 |
Diluted Weighted Average Shares | 52.2601 | 51.0125 | 48.7686 | 48.4484 | 48.2935 |
Diluted EPS Excluding Extraordinary Items | -0.32331 | -0.37148 | -0.45921 | -0.47772 | -0.50651 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.32331 | -0.37148 | -0.43672 | -0.47772 | -0.50651 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 96.967 | 154.204 | 224.493 | 282.78 | 222.502 |
Cash and Short Term Investments | 91.61 | 146.627 | 216.413 | 274.043 | 218.08 |
Cash & Equivalents | 52.418 | 45.627 | 59.444 | 46.732 | 41.471 |
Short Term Investments | 39.192 | 101 | 156.969 | 227.311 | 176.609 |
Prepaid Expenses | 4.413 | 7.241 | 6.85 | 5.363 | 1.992 |
Total Assets | 101.794 | 191.06 | 283.254 | 339.907 | 268.045 |
Property/Plant/Equipment, Total - Net | 3.938 | 7.181 | 10.731 | 13.805 | 0.557 |
Property/Plant/Equipment, Total - Gross | 5.625 | 8.388 | 12.567 | 15.005 | 1.614 |
Accumulated Depreciation, Total | -1.687 | -1.207 | -1.836 | -1.2 | -1.057 |
Goodwill, Net | 0 | 12.638 | 12.638 | 12.638 | |
Intangibles, Net | 0 | 29 | 29 | 29 | |
Long Term Investments | 0 | 27.972 | |||
Total Current Liabilities | 16.296 | 16.073 | 24.433 | 24.44 | 18.472 |
Accounts Payable | 2.493 | 2.659 | 4.598 | 1.731 | 3.693 |
Accrued Expenses | 13.803 | 13.414 | 19.835 | 16.298 | 9.679 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 19.13 | 22.131 | 42.676 | 66.69 | 57.392 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Deferred Income Tax | 0 | 2.531 | 2.531 | 3.252 | |
Total Equity | 82.664 | 168.929 | 240.578 | 273.217 | 210.653 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Common Stock | 0.049 | 0.048 | 0.034 | 0.032 | 0.025 |
Additional Paid-In Capital | 807.938 | 800.728 | 742.387 | 712.807 | 552.762 |
Retained Earnings (Accumulated Deficit) | -724.52 | -631.428 | -501.573 | -439.421 | -341.787 |
Unrealized Gain (Loss) | -0.803 | -0.419 | -0.27 | -0.201 | -0.347 |
Total Liabilities & Shareholders’ Equity | 101.794 | 191.06 | 283.254 | 339.907 | 268.045 |
Total Common Shares Outstanding | 48.895 | 48.1204 | 34.0267 | 32.5583 | 25.4954 |
Total Receivables, Net | 0.944 | 0.336 | 1.23 | 3.374 | 2.43 |
Accounts Receivable - Trade, Net | 0.944 | 0.336 | 1.23 | 3.374 | 2.43 |
Other Current Liabilities, Total | 0 | 6.411 | 5.1 | ||
Other Liabilities, Total | 2.834 | 6.058 | 15.712 | 39.719 | 35.668 |
Other Long Term Assets, Total | 0.889 | 1.703 | 6.392 | 1.684 | 3.348 |
Total Preferred Shares Outstanding | 0 | 0 | 0 | 0 | 0 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 49.672 | 64.081 | 79.744 | 96.967 | 115.078 |
Cash and Short Term Investments | 46.21 | 59.831 | 73.016 | 91.61 | 108.651 |
Cash & Equivalents | 26.656 | 21.623 | 43.482 | 52.418 | 54.673 |
Short Term Investments | 19.554 | 38.208 | 29.534 | 39.192 | 53.978 |
Total Receivables, Net | 0 | 0.342 | 0.717 | 0.944 | 1.246 |
Accounts Receivable - Trade, Net | 0 | 0.342 | 0.717 | 0.944 | 1.246 |
Prepaid Expenses | 3.462 | 3.908 | 6.011 | 4.413 | 5.181 |
Total Assets | 51.629 | 66.577 | 83.116 | 101.794 | 121.516 |
Property/Plant/Equipment, Total - Net | 1.405 | 2.164 | 3.038 | 3.938 | 4.825 |
Goodwill, Net | |||||
Intangibles, Net | |||||
Other Long Term Assets, Total | 0.552 | 0.332 | 0.334 | 0.889 | 1.613 |
Total Current Liabilities | 7.132 | 8.831 | 9.97 | 16.296 | 15.461 |
Accounts Payable | 0.758 | 0.904 | 1.224 | 2.493 | 1.942 |
Accrued Expenses | 6.374 | 7.927 | 8.746 | 13.803 | 13.519 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 9.915 | 11.628 | 12.783 | 19.13 | 19.112 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Deferred Income Tax | |||||
Other Liabilities, Total | 2.783 | 2.797 | 2.813 | 2.834 | 3.651 |
Total Equity | 41.714 | 54.949 | 70.333 | 82.664 | 102.404 |
Common Stock | 0.053 | 0.052 | 0.052 | 0.049 | 0.048 |
Additional Paid-In Capital | 816.722 | 815.588 | 814.264 | 807.938 | 805.48 |
Retained Earnings (Accumulated Deficit) | -774.786 | -760.366 | -743.47 | -724.52 | -702.125 |
Unrealized Gain (Loss) | -0.275 | -0.325 | -0.513 | -0.803 | -0.999 |
Total Liabilities & Shareholders’ Equity | 51.629 | 66.577 | 83.116 | 101.794 | 121.516 |
Total Common Shares Outstanding | 52.6142 | 52.4507 | 52.0153 | 48.895 | 48.4812 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Long Term Investments | 0 | 0 | |||
Property/Plant/Equipment, Total - Gross | 5.625 | ||||
Accumulated Depreciation, Total | -1.687 | ||||
Total Preferred Shares Outstanding | 0 | 0 | 0 | 0 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -93.092 | -129.855 | -62.152 | -97.634 | -90.751 |
Cash From Operating Activities | -84.463 | -93.396 | -62.957 | -84.067 | -64.958 |
Cash From Operating Activities | 0.498 | 0.466 | 0.691 | 0.494 | 0.643 |
Deferred Taxes | 0 | -2.531 | 0 | -0.774 | 1.099 |
Non-Cash Items | 10.253 | 49.925 | 28.813 | 23.374 | 28.256 |
Changes in Working Capital | -2.122 | -11.401 | -30.309 | -9.527 | -4.205 |
Cash From Investing Activities | 90.64 | 26.515 | 68.07 | -50.318 | -135.397 |
Capital Expenditures | -0.102 | -3.096 | -2.22 | -1.554 | -0.34 |
Other Investing Cash Flow Items, Total | 90.742 | 29.611 | 70.29 | -48.764 | -135.057 |
Cash From Financing Activities | 0.614 | 53.064 | 7.599 | 139.646 | 159.793 |
Issuance (Retirement) of Stock, Net | 0.614 | 52.806 | 6.919 | 138.899 | 159.385 |
Net Change in Cash | 6.791 | -13.817 | 12.712 | 5.261 | -40.562 |
Financing Cash Flow Items | 0.258 | 0.68 | 0.747 | 0.408 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -18.95 | -93.092 | -70.697 | -47.552 | -23.091 |
Cash From Operating Activities | -23.428 | -84.463 | -65.209 | -45.387 | -27.502 |
Cash From Operating Activities | 0.124 | 0.498 | 0.374 | 0.24 | 0.12 |
Non-Cash Items | 2.638 | 10.253 | 7.458 | 5.022 | 2.485 |
Changes in Working Capital | -7.24 | -2.122 | -2.344 | -3.097 | -7.016 |
Cash From Investing Activities | 10 | 90.64 | 74.078 | 42.646 | 33.049 |
Capital Expenditures | -0.102 | -0.102 | 0 | 0 | |
Other Investing Cash Flow Items, Total | 10 | 90.742 | 74.18 | 42.646 | 33.049 |
Cash From Financing Activities | 4.492 | 0.614 | 0.177 | 0.177 | 0 |
Issuance (Retirement) of Stock, Net | 4.492 | 0.614 | 0.177 | 0.177 | 0 |
Net Change in Cash | -8.936 | 6.791 | 9.046 | -2.564 | 5.547 |
Deferred Taxes | 0 | ||||
Financing Cash Flow Items |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Assembly Biosciences, Inc. Company profile
About Assembly Biosciences Inc
Assembly Biosciences, Inc. is a clinical-stage biotechnology company advancing a class of oral therapeutic candidates for the treatment of chronic hepatitis B virus (HBV) infection. The Company’s inhibitor product candidates include Vebicorvir (VBR), ABI-H2158 (2158), and ABI-H3733 (3733). Vebicorvir (VBR) is licensed from Indiana University and treating patients with VBR plus nucelos(t)ide analog reverse transcriptase inhibitors (NrtIs) and ultimately transitioning patients. ABI-H2158 (2158) is chemically distinct from VBR. ABI-H3733 (3733) for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan and Macau (the Territory). The Company’s research and development programs pursuing multiple drug candidates that inhibit the HBV replication cycle and block the generation of covalently closed circular DNA (cccDNA), to discover and develop finite and curative therapies for patients with HBV.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Assembly Biosciences Inc revenues decreased 92% to $6.3M. Net loss increased from $62.2M to $129.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest and other income, net decrease of 88% to $302K (income), Restructuring Charges & Provisions increase of 40% to $277K (expense).
Equity composition
Common Stock $0.001 Par, 4/11, 25M auth., 7,189,706 issd.insider control 7.88%. 07-14, 1-for-5 reverse stock split.
Industry: | Proprietary & Advanced Pharmaceuticals |
Two Tower Place
7Th Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
Income Statement
- Annual
- Quarterly
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com